. 2020 Nov 27;25(23):5569. doi: 10.3390/molecules25235569

Table 2.

Results of in vitro five-doses testing of nine human cancer types and selectivity for compounds 3c, 3d, and 3e.

Panel	Cell Line	3c					3d					3e
		GI50			TGI	LC50	GI50			TGI	LC50	GI50			TGI	LC50
		Conc. Per Cell Line	Subpanel MID ^b	Selectivity Ratio (MID ^a: MID ^b)	TGI	LC50	Conc. Per Cell Line	Subpanel MID ^b	Selectivity Ratio (MID ^a: MID ^b)	TGI	LC50	Conc. Per Cell Line	Subpanel MID ^b	Selectivity Ratio (MID ^a: MID ^b)	TGI	LC50
leukemia	CCRF-CEM	2.39	2.21	0.99	>100	>100	9.98	7.87	0.73	3.33	>3.33	2.53	2.14	1.16	>100	>100
	HL-60(TB)	3.95			3.26	>100	7.70			2.05	>3.33	2.18			6.26	>100
	K-562	1.69			--	>100	8.79			3.33	>3.33	2.43			>100	>100
	MOLT-4	1.22			5.76	>100	5.99			1.72	>3.33	2.22			8.89	>100
	RPMI-8226	2.21			--	>100	7.17			2.01	>3.33	1.86			6.47	>100
	SR	1.78			>100	>100	7.57			2.95	>3.33	1.64			--	>100
Non-Small Cell Lung Cancer	A549/ATCC	2.26	1.69	1.03	5.61	>100	8.35	5.07	1.14	2.07	>3.33	2.42	2.31	1.07	6.07	>100
	EKVX	1.39			3.46	8.60	5.01			1.15	2.64	1.87			1.25
	HOP-62	1.96			4.85	1.65	1.85			6.48	1.53	4.28			1.72
	HOP-92	1.56			4.19	>100	7.41			2.60	1.56	2.26			1.44
	NCI-H226	1.61			3.35	6.99	9.36			4.09	1.37	1.81			5.83
	NCI-H23	1.46			3.76	9.72	5.50			1.50	>3.33	1.31			4.32	>100
	NCI-H322M	1.55			2.92	5.50	1.61			5.90	1.43	1.93			5.13
	NCI-H460	1.94			3.97	8.11	1.06			3.60	1.50	3.35			1.22
	NCI-H522	1.49			4.19	>100	5.51			1.37	4.64	1.60			4.69	>100
Colon Cancer	COLO 205	1.94	2.61	0.84	4.24	9.28	3.63	5.99	0.96	9.06	2.26	3.36	2.50	0.99	1.27	6.62
	HCC-2998	1.62			3.14	6.06	9.48			2.91	1.06	2.34			6.67	2.40
	HCT-116	5.77			2.58	9.31	6.67			1.70	6.89	1.94			6.45	2.73
	HCT-15	1.52			3.50	8.07	5.49			1.18	2.54	1.51			3.24	6.96
	HT29	3.09			>100	>100	1.15			3.18	>3.33	3.32			2.87	>100
	KM12	2.68			8.80	9.05	9.99			3.56	>3.33	3.12			1.37	8.18
	SW-620	1.63			3.45	7.30	5.51			1.20	2.62	1.92			4.32	9.71
CNS Cancer	SF-268	1.68	2.79	0.78	4.48	>100	6.15	5.12	1.13	1.65	>3.33	2.54	2.43	1.02	1.10	5.91
	SF-295	1.68			3.08	5.66	6.15			1.27	2.60	3.55			1.27	3.57
	SF-539	1.69			3.12	5.79	5.54			1.02	1.89	1.67			3.06	5.58
	SNB-19	1.67			3.44	7.05	6.45			1.64	5.31	3.09			1.17	3.42
	SNB-75	8.43			2.76	7.79	1.32			7.46	1.74	1.32			6.04	2.51
	U251	1.60			4.28	>100	5.12			1.12	2.43	2.41			1.11	>100
Melanoma	LOX IMVI	5.32	2.32	0.95	2.10	5.86	4.06	5.77	1.00	9.04	2.01	9.66	3.12	0.79	2.62	6.98
	MALME-3M	3.83			1.58	4.00	4.42			8.70	1.71	5.70			1.75	4.19
	M14	1.63			3.30	6.65	5.54			1.06	2.01	1.33			2.83	6.03
	MDA-MB-435	1.94			3.63	6.82	5.98			1.09	1.97	1.76			3.23	5.93
	SK-MEL-2	1.74			4.32	7.27	7.39			1.58	9.60	2.47			7.25	9.29
	SK-MEL-28	1.87			3.35	6.00	6.87			1.21	2.15	2.40			5.22	1.39
	SK-MEL-5	1.41			2.75	5.37	5.51			1.02	1.89	1.43			2.76	5.32
	UACC-257	1.55			3.15	6.39	5.93			1.14	2.20	1.69			3.41	6.88
	UACC-62	1.63			3.91	9.38	6.23			1.33	2.84	1.62			3.52	7.66
Ovarian Cancer	IGROV1	1.13	2.25	0.98	3.21	9.08	4.46	5.38	1.07	1.31	5.78	1.16	2.53	0.98	4.74	2.58
	OVCAR-3	3.28			1.43	5.03	5.22			1.28	3.16	1.53			4.42	1.59
	OVCAR-4	1.26			2.56	5.18	4.54			8.87	1.73	1.61			4.58	1.59
	OVCAR-5	2.03			4.37	9.42	5.86			1.15	2.26	1.83			3.53	6.79
	OVCAR-8	2.13			1.12	>100	5.81			1.24	2.63	2.62			1.16	4.10
	NCI/ADR-RES	2.24			--	>100	7.43			2.17	>3.33	1.93			6.77	>100
	SK-OV-3	3.70			2.34	>100	4.35			8.75	1.76	7.03			2.14	5.23
Renal Cancer	786-0	2.30	2.25	0.98	5.70	>100	7.48	4.82	1.20	1.70	>3.33	2.75	2.53	0.98	7.93	9.61
	A498	1.05			4.70	>100	6.93			2.90	>3.33	2.07			6.34	>100
	ACHN	1.42			2.91	5.96	4.92			9.65	1.89	1.39			3.03	6.60
	CAKI-1	1.18			2.86	6.92	4.80			2.14	8.98	2.48			1.49	3.87
	RXF393	1.35			2.71	5.43	5.02			9.86	1.94	1.85			4.75	1.50
	SN12C	1.22			2.79	6.42	5.06			1.07	2.24	1.33			2.61	5.11
	TK-10	4.48			8.14	4.13	1.03			1.71	2.85	1.84			3.47	6.54
	UO-31	4.96			2.09	4.60	3.34			8.60	2.21	8.50			2.77	7.85
Prostate Cancer	PC-3	1.49	1.67	1.32	8.81	>100	6.20	6.29	0.92	2.69	>3.33	1.62	1.74	1.43	1.07	>100
Prostate Cancer	DU-145	1.85	1.67	1.32	3.45	6.46	6.37	6.29	0.92	1.19	2.22	1.85	1.74	1.43	3.43	6.36
Breast Cancer	MCF7	1.23	1.73	1.27	3.36	9.17	5.83	6.67	0.87	1.28	2.82	1.42	1.90	1.31	3.29	7.62
	MDA-MB-231/ATCC	1.27			6.69	>100	6.52			2.69	>3.33	1.37			9.82	>100
	HS 578T	2.04			6.93	>100	7.82			2.05	>3.33	2.09			6.03	>100
	BT-549	1.53			2.91	5.54	5.22			9.83	1.85	1.50			2.91	5.64
	T-47D	2.03			7.29	>100	6.98			2.30	>3.33	2.49			1.44	>100
	MDA-MB-468	2.28			5.72	>100	7.66			2.04	>3.33	2.55			7.32	>100
MID ^a	2.20						5.77					2.48

MID ^a = Average sensitivity of all cell lines in mM and MID ^b = average sensitivity of all cell lines of a particular subpanel in µM.